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Abstract
Glioblastoma (GBM) is a highly infiltrative brain tumor in which cells with properties of stem
cells, called glioblastoma stem cells (GSCs), have been identified. In general, the dominant
view is that GSCs are responsible for the initiation, progression, invasion and recurrence of
this tumor. In this study, we addressed the question whether the differentiation status of
GBM cells is associated with their invasive capacity. For this, several primary GBM cell
lines were used, cultured either as neurospheres known to enrich for GSCs or in medium
supplemented with 10% FCS that promotes differentiation. The differentiation state of the
cells was confirmed by determining the expression of stem cell and differentiation markers.
The migration/invasion potential of these cells was tested using in vitro assays and intracra-
nial mouse models. Interestingly, we found that serum-induced differentiation enhanced the
invasive potential of GBM cells, which was associated with enhanced MMP9 expression.
Chemical inhibition of MMP9 significantly reduced the invasive potential of differentiated
cells in vitro. Furthermore, the serum-differentiated cells could revert back to an undifferenti-
ated/stem cell state that were able to form neurospheres, although with a reduced efficiency
as compared to non-differentiated counterparts. We propose a model in which activation
of the differentiation program in GBM cells enhances their infiltrative potential and that
depending on microenvironmental cues a significant portion of these cells are able to revert
back to an undifferentiated state with enhanced tumorigenic potential. Thus, effective ther-
apy should target both GSCs and differentiated offspring and targeting of differentiation-
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associated pathways may offer therapeutic opportunities to reduce invasive growth of
GBM.
Introduction
Glioblastoma (GBM) is an extremely aggressive and clinically difficult to treat cancer that is in
part caused by its highly invasive nature [1, 2]. In GBM, tumor initiating stem cells or cancer
stem cells (CSCs) have been identified and are commonly referred to as glioblastoma stem cells
(GSCs) [3–5]. In vitro GSCs are known to be enriched in spherical floating structures, named
neurospheres, when cultured in serum-free medium containing bFGF and EGF, which main-
tains these cells in a largely stem cell or undifferentiated state [6–8]. GSCs are characterized by
enhanced tumor initiation potential in comparison to non-GSCs that can be preclinically
determined by neurosphere formation and tumor growth potential in immunocompromised
mice [4]. Like normal neuronal stem cells (NSCs), which can differentiate into neurons, astro-
cytes and oligodendrocytes [9, 10], GSCs can also differentiate into similar cell lineages [11].
GSCs have been shown to be highly resistant to chemo- and radiotherapy indicating that these
cells may be responsible for tumor relapse after therapy [12, 13].
The highly invasive growth pattern of GBM into the normal brain parenchyma limits the
efficacy of surgical intervention leading to the poor prognosis of patients diagnosed with GBM.
Nonetheless, surgical debulking in combination with chemo-radio therapy remains the main-
stay treatment strategy for GBM [14, 15]. The invasive and diffuse growth pattern of malignant
gliomas was recognized by neurosurgeons decades ago; super-radical resections using hemi-
spherectomies even failed to eradicate the tumor cells and led to relapse and formation of sec-
ondary lesions in the other hemisphere [16, 17]. Several studies have indicated enhanced
invasive potential of GSCs and their involvement in relapse of GBM [18–20]. It is also broadly
believed that in epithelial cancers CSCs have elevated invasive potential, which might contrib-
ute to “metastatic colonization” in distant organs leading to cancer-related mortality [21, 22].
As CSCs possess tumor-initiating capacity, which is mandatory for the establishment of sec-
ondary tumor in distant organs, it is compelling to argue that CSCs are more invasive in
nature.
In the current study we addressed the question whether undifferentiated GBM neuro-
sphere-cultured cells have elevated invasive potential when compared to serum-differentiated
counterparts using in vitro and in vivo assays. In addition, the involvement of Matrix metallo-
proteinase-9 (MMP9) in tumor invasion was examined. We propose a model in which early
differentiated GBM cells are most invasive and depending on cues of the microenvironment
are able to revert back to a stem cell state facilitating tumor propagation.
Materials and Methods
The primary material used in this study was surgical leftovers obtained from anonymous GBM
patients. The material was obtained after approval and following the ethical guidelines of the
Medical Ethics Review Committee (METC) of the University Medical Center Groningen
(UMCG).The animal experiments described in this manuscript were approved by the Animal
Ethical Committee (DEC) and conducted in compliance with the Animal Welfare Act Regula-
tions. Care was taken at every step to minimize suffering to the animals by the correct adminis-
tration of anesthesia and analgesic agents whenever needed. Further the animals were
monitored daily by the researcher (JJ). The animal welfare officer of the Central Animal Facility
(CDP), UMCG also monitored the animals twice a week.
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Cell culture and treatments
GG1, GG9, GG12, GG14 and GG16 cells were newly generated from left over GBM primary
material under approval and following the ethical guidelines of the Institutional Review Board
of the UMCG and as described elsewhere [23]. The cells were found to represent different
molecular subtypes, GG1 and GG16 mesenchymal (MES) and GG9, GG12 and GG14 pro-
neural (PN). Cells were propagated as neurospheres in neural stem cell medium (NSM) which
is composed of-Neurobasal A-Medium (Gibco Life Technologies, Bleiswijk, The Netherlands)
supplemented with 2% B27 supplement (Gibco Life Technologies), 20ng/ml EGF (R&D sys-
tems, Abingdon, UK), 20 ng/ml bFGF (Merck-Millipore, Billerica, MA, USA), 1% pen/strep
and 1% L-glutamine (Gibco Life Technologies). The GBM cell line GSC23 (PN) was a kind gift
from dr. H. Colman (University of Utah, Salt Lake City, USA) and was described previously
[24]. Neurospheres were differentiated by first pelleting and washing cells with PBS followed
by accutase (Sigma-Aldrich, St Louis, MO) treatment and repeated pipetting in NSMmedium
to dissociate cells. The single cell suspension was seeded on poly-L-lysine- (P8920, Sigma-
Aldrich) or laminin-coated plates (L4544, Sigma-Aldrich) in differentiation medium contain-
ing- Neurobasal-A medium supplemented with 10% foetal calf serum, 2 mM L-glutamine, 100
units/mL penicillin and 100 μg/ml streptomycin (Gibco Life Technologies) for 10 days, with
media changes every 2–3 days.
Cells were maintained at 37°C in a humidified atmosphere with 5% CO2. When indicated,
cells were treated with small molecule inhibitor of MMPs, CP 471474 (Axon Medchem, Gro-
ningen, The Netherlands). The inhibitor was added at a concentration of 50 and 100 nM 24 hrs
prior to using the cells for experiments.
Immunofluorescence microscopy
Neurospheres were dissociated and seeded on poly-L-lysine-coated coverslips and allowed to
differentiate for 10 days in medium supplemented with 10% FCS with a medium change every
3 days. Whole differentiating neurospheres were seeded on poly-L-lysine-coated coverslips in
medium supplemented with 10% FCS and after 5 days cells were fixed using 4% para-formalde-
hyde for 10 minutes at room temperature. After another PBS wash the cells were permeabilized
with ice-cold 0.1% Triton X-100 (X100, Sigma-Aldrich) in PBS for 10 minutes at room temper-
ature, washed again and incubated in PBS containing 2% normal goat serum (X0907, Dako,
Glostrup, Denmark), 2% BSA (PAA Laboratories GmbH, Colbe, Germany) and 1% Tween 20
(P2287, Sigma-Aldrich) for 1 h at room temperature. Cells were stained for 1.5 h at room tem-
perature with primary antibodies against β III-Tubulin (ab76287, Abcam, Cambridge, UK),
GFAP (Z0334, Dako), SOX2 (4900, Cell Signaling Technology, Danvers, MA). Subsequently,
cells were washed with PBS and incubated with secondary antibodies goat anti-rabbit Cy3
(AP132C, Merck Millipore) or goat anti-mouse Alexa Fluor 488 (A-21121, Thermo Fisher Sci-
entific, Waltham, MA) at a concentration of 1:200 for 1 h at room temperature.
Hoechst (Sigma-Aldrich H6024) staining was performed for 5 minutes followed by mount-
ing the coverslips with Kaisers glycerin (Merck Milipore). Cells were examined by fluorescent
microscopy (Leica DM6000, Leica Microsystems GmbH, Mannheim, Germany) and images
were captured using Leica DFC360 FX camera.
Wound healing assay
Six-well plates were coated with 1:10 diluted poly-L-lysine and 0.5 μg/ml laminin (L4544,
Sigma-Aldrich). Cells were most suitable for use in this assay since the adhere seeded at a den-
sity of 2x105 cells/well. Neurospheres were dissociated and single cells were grown in NSM
medium until a monolayer was formed. For the differentiated condition, cells were grown in
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differentiation medium for 10 days, with medium changes every 2–3 days, until a monolayer
was formed. A scratch was made in the monolayer by manually scraping with a 10 μl pipette
tip and the medium was aspirated to remove detached cells. GSC23 cells remained well
attached to the plates after scratching making them most suitable for use in this assay. The cells
were then incubated with medium supplemented only with 10% FCS for 24 h. Images were
acquired with a Leica camera mounted on an inverted microscope and were processed using
image J software. The distance cells migrated was determined by measuring the wound area
after 24 h corrected for the wound area at time 0 h. The values obtained were expressed as a
migration percentage, setting the gap width at 0 h as 0%.
Limiting dilution assay
Undifferentiated and differentiated cells were sorted based on the forward and sideward scatter
pattern using a flow cytometer (BD Biosciences, San Jose, CA). Single cells were seeded in
96-well plates at a density of 10, 20 or 40 cells/well in a volume of 150 μl NSM; per cell density,
3 plates was used and cells were replenished with 75μl of NSM every 5 days. After 3 weeks, the
number of neurospheres per well were counted.
Western blotting
Western blotting was performed as described previously [23]. Membranes were probed over-
night at 4°C with the following primary antibodies: β III Tubulin (ab76287, Abcam), GFAP
(Z0334, Dako), SOX2 (4900, Cell Signaling), Nestin (sc-23927, Santa Cruz Biotechnology
INC), MMP9 (ab76003, Abcam), Rabbit-α-mouse (1:1500; P0260, Dako) and goat-α-rabbit
(1:1500; P0448, Dako). HRP-conjugated secondary antibodies were used for detection using
Lumi-LightPLUS Western Blotting Substrate (12015196001, Roche Life Sciences, Branford, CT).
Membranes were probed with β-actin antibody (0869100, MP Biomedicals, Santa Ana, CA) to
confirm equal loading. MMP9 bands were quantified by densitometry and their intensities
were corrected for the corresponding β-actin bands; the intensity in neurospheres was set at 1.
Transwell invasion assay
The invasion potential was determined on collagen-coated Transwell inserts with 8μm pore
size (Becton Dickinson B.V., Breda, The Netherlands). GG16 cells proliferated fast and main-
tained some proliferative properties after differentiation and were used in this assay. Cells were
trypsinized and resuspended in 0.1% FCS containing medium. 150μl of a cell suspension con-
taining 5 x 104 cells were added to the Transwell in triplicates per condition. 10% FCS or 0.1%
FCS was added to the lower wells as chemoattractants. Cells that migrated/ invaded and
appeared on the bottom surface of the Transwell insert membrane were fixed with 75% metha-
nol/25% acidic acid for 20 min and stained with 0.25% Coomassie blue in 45% methanol/10%
acetic acid followed by washing with demi water. The membranes were subsequently cut out
and mounted on microscopic slides for quantification. Representative pictures of the mem-
branes with cells were acquired at 5x magnification and the total number of cells on fifty indi-
vidual fields per membrane was counted; average numbers and standard deviation of invading
cells for every condition were calculated.
Intracranial Injection mouse model
GG16 neurospheres (GG16 Nsp) and differentiated (GG16 Dif.) cells were prepared for intra-
cranial injection in NOD scid gamma mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ)/ NSG mice
(inbred strains obtained from Central Animal Facility, Groningen). 3x105 GG16 Nsp and
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GG16 Dif. cells were injected in the striatum of the animals (6 mice for each condition) using a
stereotactic frame to determine tumorigenicity and invasive growth. Mice were monitored on a
regular basis. At day 7 and day 21 post implantation of the cells the animals were perfused
under anesthesia with PBS and 4% paraformaldehyde as described earlier [25]. The brains were
harvested and fixed in 4% para-formaldehyde for 24 hrs at 4°C and embedded in paraffin and
prepared for IHC. These experiments were approved by the committee for Animal care, and
conducted in compliance with the Animal Welfare Act Regulations.
For quantifying tumor invasion, from each mouse brain 4 to 6 serial sections were evaluated
for infiltrating tumor cells after immunohistochemical staining for Nestin that specifically
stains the implanted tumor cells. A cell was considered infiltrating when (1) it was positioned
outside the core or the original implantation site with preexistent mouse brain cells lying in
between the core and the infiltrating cells and (2) Nestin staining was present around a clearly
visible nucleus.
Quantitative real-time polymerase chain reactions (RT-PCR)
Total RNA was isolated from either neurospheres or differentiated GBM cells using RNeasy
mini kit (Qiagen, Hilden, Germany) as per the instruction of the manufacturer. 1μg of total
RNA was used to reverse transcribe into cDNA by a RNase H+ reverse transcriptase using
iScript cDNA synthesis kit (BioRad, Hercules, CA) as per manufacturer’s instructions. The
cDNAs were stored at -20°C until used for quantitative RT-PCR. Real-time (RT)-PCR was per-
formed in an ABI PRISM 7900HT Sequence Detector (Applied Biosystems, Foster City, CA)
with the iTaq SYBR Green Supermix with Rox dye (Biorad) and amplification was performed
with the following cycling conditions: 5 min at 95°C, and 40 two-step cycles of 15 sec at 95°C
and 25 sec at 60°C. The reactions were analyzed by SDS software (Version 2.4, Applied Biosys-
tems, Foster City, CA). The threshold cycles (Ct) were calculated and relative gene expression
was analyzed after normalizing for GAPDH, house-keeping gene. Human primers used are
listed in S1 Table. For meta-gene analysis, fold induction were log transformed and data was
imported to Genesis software (Graz University of Technology, Graz, Austria (genome.tugraz.
at/genesis)) for performing clustering and heatmap visualization.
Immunohistochemistry
Coronal sections of 3 μm thickness were prepared from mouse brains injected with GBM cells.
The sections were dried overnight at 55°C. Prior to staining, tissues were deparaffinized in xylol
and rehydrated in graded series of ethanol. Antigen retrieval was required for Ki-67, MMP-9 and
Nestin through microwave pretreatment with Tris/EDTA, Tris/HCl or citrate buffer, respectively.
Subsequently endogenous peroxidase was blocked for 30 minutes using 0.3% H2O2 at room
termperature (RT). Then slides were incubated with primary antibodies diluted in 1% BSA/PBS
for 1 hour at RT. Antibodies used were GFAP (Z0334, Dako) diluted 1:250, Ki-67 (MIB-1, Dako)
diluted 1:300, MMP-9 (C-20, Santa Cruz Biotechnology INC) diluted 1:50, and Nestin (10C2,
Santa Cruz Biotechnology INC) diluted 1:100. Secondary and tertiary antibodies were diluted in
1% BSA/PBS and supplemented with 1% AB-serum and incubated for 30 minutes at RT. Staining
was visualized by 3,3’-diaminobenzidine incubation for 10 minutes and sections were counter-
stained with haematoxylin and mounted. Images were acquired using a C9600 NanoZoomer
(Hamamatsu Photonics KK, Hamamatsu City, Japan).
Statistical Analysis
In-vitro data were represented as the mean ± standard error of the mean (SEM) using the
GraphPad Prism version 5.01 (GraphPad for Science, San Diego, CA). Two tail unpaired
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student’s t-test was used for calculating statistical significance between two groups was unless
otherwise mentioned in the figure legends. p values< 0.05 were assumed as statistically signifi-
cant for all the tests. Differences in the number of infiltrating cells in mouse brain slices of ani-
mals implanted with neurospheres or differentiated cells were calculated by Mann-Whitney
tests.
Results
Serum-induced differentiation of GBM cells
GSC23, GG1, GG9, GG12, GG14 and GG16 cell lines were propagated as neurospheres or
exposed to 10% FCS for 10 days to induce differentiation, similar as described by Singh et al
[3]. Upon differentiation the cells adhered and acquired mostly a typical star shaped glial mor-
phology (Fig 1A). To further confirm differentiation, cells were stained for the presence of
astrocytic GFAP and neuronal β3 Tubulin markers using immunofluorescence microscopy.
Both lineage specific markers were detected, though at varying intensity and with GFAP
expression being mostly enhanced after FCS-induced differentiation and GG14 cells only
showing significant elevation in β3 Tubulin expression upon differentiation (Fig 1B and 1C).
On the other hand, the expression of the stem cell marker SOX2 overall appeared to decrease
upon differentiation, although to variable extends (Fig 1C).
Serum-induced differentiation enhances migration and invasion in vitro
When whole GSC23 neurospheres were seeded on poly-L-lysine-coated coverslips and subse-
quently exposed to 10% FCS for 5 days, we noted that adherent cells started radiating out of
the neurospheres (Fig 2A). Upon immunofluorescent staining for SOX2 and GFAP, interest-
ingly, we observed that SOX2-expressing cells appear to be more confined to the core structure
of the neurospheres, while the cells that migrated out of the spheres lost SOX2 expression and
gained that of GFAP. This suggested to us that serum-differentiated GSC23 cells have potent
migratory properties that may possibly exceed that of undifferentiated cells.
To further compare the migratory potential of undifferentiated and serum-differentiated
GBM cells wound healing assays were performed. For this, monolayer GBM cell cultures in
serum-free medium were established on laminin-coated dishes that previously were shown to
retain GSC characteristics [26]. Indeed, the expression patterns of Nestin and the GSC associ-
ated marker SOX2 and the differentiation marker GFAP were similar between laminin- and
neurospheres cultured GSC23 cells, reflecting their undifferentiated states (Fig 2B and 2C).
Wound closure was monitored after 24 hours and showed that differentiated GSC23 cells have
an approximately 8-fold higher migratory capacity than the undifferentiated counterparts (Fig
2D and 2E). Similarly, collagen-coated transwell inserts were used to evaluate the invasive
potential of differentiated and undifferentiated GG16 cells (Fig 2F and 2G). GG16 differenti-
ated cells showed already an increase in basal invasion capacity of ~ 6 fold compared to the
undifferentiated cells, which was strongly enhanced upon addition of 10% FCS as chemoattrac-
tant and differentiated cells displayed more than 2-fold higher level of invading cells. In sum-
mary it is evident that in an in vitro setting serum-differentiated cell are more migratory and
invasive than undifferentiated cells.
Serum-differentiated GBM cells show enhanced infiltrating potential in
vivo
Next, we compared the behavior of tumors originating from either differentiated or undifferenti-
ated GBM cells upon intracranial implantation. For this serum-differentiated and undifferentiated
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GG16 cells were injected into the striatum of NSGmice (n = 6 per condition) and at day 7 (n = 3)
and day 21 (n = 3) post-injection the animals were sacrificed and brains harvested for immuno-
histochemical analysis. Nestin staining allowed the comparison of tumor cell infiltration (Fig 3A
and 3B). Quantification of the number of infiltrating cells showed a time-dependent increase in
infiltrating cells. However, the number of infiltrating cells is larger in the serum-differentiated
group compared with the neurospheres group. The median cell numbers infiltrating in the neuro-
sphere group at 7 days was 6, and at 21 days 20; in the differentiated group at 7 days was 20,
and at 21 days 86,5 (Fig 3B). There was no significant difference in proliferative potential as indi-
cated by similar Ki67 staining patterns between the tumors derived from differentiated and undif-
ferentiated cells (S1 Fig). At day 7 post-injection most of the tumor cells were largely negative for
Fig 1. Serum inducesmainly astrocytic differentiation in neurospheres. a. Pictures of neurosphere cultured and differentiated adherent monolayers of
six different cell lines, GSC23, GG1, GG9, GG12, GG14, GG16 (magnification x10). b. Immunostaining for astrocytic (GFAP) and neuronal (β3 Tubulin)
differentiation markers in differentiated GSC23, GG1 and GG9 (magnification x20; GFAP and β3 Tubulin in red and DAPI in blue). c.Western blot detecting
the expression of stem cell marker SOX2 and differentiation markers GFAP and β3 Tubulin in differentiated and undifferentiated GSC23, GG1, GG9, GG14
and GG16.
doi:10.1371/journal.pone.0145393.g001
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GFAP in both groups with few cells showing positive staining. However, at day 21 the GFAP lev-
els in the tumor increased in both groups, with particularly 1 out of the 3 animals in the differenti-
ated group showed a strong increase in GFAP levels (Fig 3C). Also note that the expression of
GFAP in GG16 cells was relatively low compared to the other GBM cells in vitro and that the
brain microenvironment apparently also induces GFAP expression, i.e. differentiation (Fig 1C)
and may explain the relative low expression of GFAP in the GG16 xenografts. Overall we
obtained evidence that serum-differentiated GG16 cells have elevated invasive potential in com-
parison to the undifferentiated cells in the intracranial mouse model.
Serum-differentiation leads to enhanced MMP9 expression and
chemical inhibition of MMP9 reduces invasion in vitro
MMP9 belongs to a large family of proteases that play important roles in degrading the extra-
cellular matrix thereby facilitating tumor invasion [27]. Also in GBM an important role for
MMP9 has been reported in mediating invasion and migration [28, 29]. Therefore, we studied
the possible involvement of MMP9 in our models, GG1, GG16, GG14 and GSC23. We
observed that FCS-differentiated cells expressed a significantly higher level of MMP9 compared
to the undifferentiated cells (Fig 4A; quantified data are depicted in S2 Fig). Overall little or no
elevation in the level of MMP2 was observed following differentiation in none of the cell lines
used in this study (S3 Fig). In parallel, immunohistochemical staining for MMP9 on the intra-
cranial tumors also showed elevated MMP9 expression in xenografts derived from FCS-differ-
entiated GG16 cells; particularly MMP9 expression appeared higher in tumor cells that were
moving out of the main tumor mass and invading the normal brain (Fig 4B). In addition, also
note some MMP9 expression in the tumor cores, which may reflect differentiation of cells and
is in agreement with the presence of GFAP (see Fig 3B).
In order to further validate the role of MMP9 in mediating the enhanced invasive potential of
differentiated cells we used a selective chemical MMP inhibitor (MMPi) (CP471474) known to
potently block MMP9 activity with an IC50 value of 13nM [30]. At 50nM and 100nM for 24 h the
inhibitor also induced a significant reduction of MMP9 expression at the protein level in the differ-
entiated GG16 cells (Fig 4C). In transwell assays pretreatment of differentiated GG16 cells with
CP471474 (100nM) led to a significant reduction of approximately 30% in invasive potential when
compared to untreated cells (Fig 4D and 4E). On the other hand, the administration of CP471474
did not significantly reduce the proliferation potential of GG16 cells both in number and size of
spheroids formed in a limiting dilution assay (S3 Fig). Together this indicates that differentiation-
enhanced invasive capacity is associated with increased expression and activity of MMP9.
Serum-differentiated GBM cells can partially revert back to an
undifferentiated state and reacquire spheroid forming potential
Our experiments thus far indicated that serum-differentiated GBM cells have enhanced inva-
sive capacity and appeared at least equally tumorigenic upon intracranial implantation in mice
Fig 2. Serum-induced differentiation enhancesmigration and invasion in vitro. a.GSC23 whole neurosphere differentiation on poly-l-lysine coated
cover slips in media containing serum, along with co-immunostaining with SOX2 (green) and GFAP (red; DAPI in blue; magnification x10). b. Inverted
microscope images of GSC23 neurospheres and undifferentiated monolayer GSC23 cells cultured in serum free medium on laminin-coated plates
(magnification x10). c.Western blot showing the expression of Nestin and the stem cell marker SOX2 and differentiation marker GFAP in the neurospheres
and undifferentiated laminin-coated GSC23 monolayer cells. d.Wound healing assay performed with differentiated monolayer and undifferentiated laminin-
coated monolayer GSC23 cells showing differences in wound closure capacity (magnification x5), quantification of wound closure of 3 independent
experiments are shown in (e) (**** p<0.0001). f. Representative pictures (magnification x5) of transwell membranes comparing the invading capacity of
differentiated and undifferentiated GG16 cells; quantification shown in g. The bars represent the mean of three independent experiments measured in
triplicate ± SEM (*P < 0.05, ***P < 0.001).
doi:10.1371/journal.pone.0145393.g002
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Fig 3. Serum-differentiated GBM cells show enhanced infiltration in vivo. a. Immunohistochemical staining with Nestin on xenografts derived from
differentiated (GG16D) and undifferentiated (GG16 Nsp) at day 7 and day 21 post intracranial injection; overview (magnification x5) and enlarged picture
(magnification x20) are being shown. b.Mann-Whitney U tests showing significant differences in the number of infiltrating cells between implanted
neurosphere and differentiated cells, both at 7 days (p = 0,001) and 21 days (p = 0,004). The average number of infiltrating cells per section and standard
deviations are indicated. c. Immunohistochemical staining with GFAP.
doi:10.1371/journal.pone.0145393.g003
Differentiation Stimulates Invasion in Glioblastoma
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in comparison to the undifferentiated counterparts. Since, according to the CSC model, GBM
cells with stem cell characteristics are most tumorigenic, we explored the possibility that differ-
entiated GBM cells may be able to revert back to a stem cell state. Therefore we compared the
neurosphere forming potential of undifferentiated and differentiated GSC23, GG1, GG9,
GG14 and GG16 cells. Serum-induced differentiated cells, when placed back in serum-free
medium started forming neurospheres. These, so called secondary neurospheres, showed in
some cases a reduction in size (GG1, GG9, GG14) or were similar to the primary neurospheres
(GSC23 and GG16) (Fig 5A and 5B). In secondary neurospheres of GG9 and GG16 the expres-
sion level of GFAP was also significantly reduced compared to the differentiated counterparts,
similar to levels seen in the primary neurospheres (Fig 5C). Limiting dilution assays demon-
strated a significant reduction in neurosphere formation potential of the GSC23, GG9, GG14
and GG16 differentiated cells in comparison to the undifferentiated counterparts (Fig 5D). The
number of neurospheres formed was proportional to the number of cells seeded for each cell
line. This effect was most pronounced in GG9 cells, showing a reduction of approximately 75%
in neurosphere forming capacity of differentiated cells, and was least detectable in GG16 cells
with a reduction of around 25 to-50%.
Dedifferentiation of differentiated GG16 cells leads to decreased
invasive potential
The differentiation state of primary and secondary GG16 neurospheres and differentiated
GG16 cells was confirmed by qRTPCR and showed a loss of stem cell markers in differentiated
cells compared to the primary and secondary neurospheres, and a gain of differentiation asso-
ciated gene expression (Fig 6A). Next, the invasive potential was determined in parallel for
GG16 primary and secondary neurospheres and serum-differentiated counterparts. It was
observed that cells from primary and secondary neurospheres had equal levels of invasive cells,
and their invasive capacity was approximately 50% reduced compared to differentiated GG16
cells (Fig 6B and 6C). Furthermore, the expression of MMP9 was also reduced upon dediffer-
entiation of GG16 cells (Fig 6D).
Discussion
The poor prognosis associated with GBM is at least in part due to the high infiltration of GBM
cells into the normal brain parenchyma. This makes full surgical resection of the tumor virtu-
ally impossible [1, 15]. CSCs in GBM have been associated with several of the aggressive char-
acteristics of GBM such as high tumor vascularization, invasive behavior, chemo- and radio-
resistance and relapse of disease after surgery [1, 2, 31]. These GSCs possess self-renewal ability
and high tumor-initiating potential and are able to differentiate into bulk tumor cells that are
commonly believed to lack tumor forming ability [3, 4, 31]. Partially in contrast with this view,
our present study shows in in vitro assays that serum-differentiated GBM cells have higher
migratory and invasive capacity than undifferentiated neurosphere cultured counter parts that
are enriched for GSCs. Further, the tumors originating from intracranial implanted
Fig 4. Serum-differentiation leads to enhancedMMP9 expression. a.Western blot showing MMP9 expression in differentiated and undifferentiated
GSC23, GG1, GSC14 and GG16 cells. The numbers (SD between parentheses) indicate the intensity of the quantified bands corrected for loading (β-actin)
and the level in neurospheres was set at 1. b. Immunohistochemical staining for MMP9 on xenografts derived from differentiated and undifferentiated GG16
at day 7 and day 21 post intracranial injection showing elevated MMP9 expression in xenografts derived from the differentiated cells in comparison to the
undifferentiated cells; overview (magnification x5) and enlarged picture (magnification x20). c.Western blot showing a decrease in MMP9 expression in
differentiated GG16 cells following the administration of CP 471474, a chemical inhibitor of MMP9. d. Representative pictures (magnification x5) of transwell
membranes showing a reduction of the invading capacity of differentiated GG16 cells following pre-treatment with the MMP9 inhibitor; quantification is shown
in e. Data represent the means ± SEM of 3 independent experiments where 30 neurospheres were included in each experiment (****P < 0.0001).
doi:10.1371/journal.pone.0145393.g004
Differentiation Stimulates Invasion in Glioblastoma
PLOSONE | DOI:10.1371/journal.pone.0145393 December 23, 2015 12 / 19
Differentiation Stimulates Invasion in Glioblastoma
PLOSONE | DOI:10.1371/journal.pone.0145393 December 23, 2015 13 / 19
undifferentiated or serum-differentiated cells also showed differences in tumor invasion, with
tumors originating from the serum-treated cells showing elevated invasion along the lateral
border at day 7 and 21 post intracranial implantation of the tumor cells. Following serum-dif-
ferentiation, upregulation of MMP9 was detected in GBM cells and elevated expression of
MMP9 was also noticed in the invading tumor cells originating from the serum-differentiated
cells in comparison to the tumors that originated from the undifferentiated cells.
The association of elevated expression of MMP9 with enhanced invasive potential in GBM
has been previously reported [28, 29, 32, 33]. For tumor cell invasion interactions with the
ECM needs to be modified for allowing cells to move into more distant parts of the brain. Deg-
radation of the ECM is known to be facilitated by the secretion of proteolytic enzymes such as
the plasminogen activators and the MMPs, and in GBMMMP2 and MMP9 have been con-
nected to invasion [34]. Indeed, we found that the chemical inhibition of MMP9 by MMP
inhibitor (MMPi)-CP 471474 in differentiated GG16 cell significantly reduced their invasive
potential in vitro, showing that migration and invasion are at least in part linked with the pres-
ence of MMP9.
Earlier studies have associated CSCs with a high migratory capacity. For example, the exis-
tence of migrating CSCs has been proposed that disseminate by undergoing EMT and at the
same time retain stem cell functionality allowing metastatic colony formation [35–37]. The
presence of such migrating CSCs with distinct features compared to the regular CSC compart-
ment has not been confirmed as yet in GBM. However, previously it was demonstrated that
CD133 positive GSCs have enhanced invasive capacity when compared to the non-GSC
CD133 negative cell fractions [19]. On the other hand, Weber et al. reported lower migration
capacity of GSCs represented by the side population in Hoechst exclusion assays, when com-
pared to the non-side population [38]. Regardless of the validity of the different CSC markers
used and apparent contrasting conclusions of these reports, these studies did not compare the
effect of serum-induced differentiation on invasiveness.
Campos et al. reported that CD133 positive GSCs treated with serum and all-trans-retinoic
acid reduced their tumorigenicity and invasive behavior, the latter being associated with
reduced MMP2 expression [39]. However, contrary to our experiments in which serum-differ-
entiated and undifferentiated neurosphere cells were directly compared for invasive capacity,
the authors used pre-formed neurospheres that were exposed to differentiation-inducing
medium after which invasion was monitored for long time periods, up to 12 days.
Interestingly, we also observed that the serum-differentiated cells could revert back to an
undifferentiated state upon seeding in serum-free medium suggestive of de-differentiation.
Indeed this was associated with reduced expression of differentiation markers and gain of stem
cell markers. Along with this the serum-differentiated GBM cells were able to form neuro-
spheres, although with a reduced capacity (2- to 4-fold) when compared to the undifferentiated
counterparts. Of note, the invasive capacity of the de-differentiated cells (secondary neuro-
spheres) also decreased and became comparable to that of the undifferentiated parental cells
(primary neurospheres), and was accompanied by a down-regulation of MMP9 levels.
Although serum is often used as an inducer of differentiation in GBMmodels in vitro, it
should be noted that exposure times likely affect the degree of differentiation. For example, Lee
Fig 5. Serum-differentiated GBM cells can revert back to an undifferentiated state and re-acquire stemness. a. Serum-differentiated GSC23, GG1,
GG9, GG14 and GG16 (primary) neurospheres (Nsp) reverted back to (secondary) neurospheres following exposure to neural stem cell medium (NSM). b.
Quantification of the size of primary and secondary GG9 and GG16 neurospheres. (***P<0.001). c.Western blot showing the expression level of GFAP in
undifferentiated (primary Nsp), differentiated and de-differentiated (secondary Nsp) GG9 and GG16 cells. d. Limiting dilution assay showing the reduction in
the neurosphere formation potential in GSC23, GG9, GG14 and GG16 following differentiation. Data represent the means ± SEM of 3 independent
experiments and neurospheres were counted from 96 wells in each experiment (**P<0.01, ***P < 0.001).
doi:10.1371/journal.pone.0145393.g005
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et al. reported differences in characteristics between short and long time period serum exposed
GBM neurospheres with respect to their neurosphere forming ability and tumorigenicity [6].
In the current study we used serum-differentiation conditions as earlier described by Singh
et al [3], representing shorter exposure times than used by Lee et al. [6] and possibly leading to
more early differentiation stages. Regardless of this, our findings indicate that GBM neuro-
sphere cells pushed out of the stem cell state by serum, as evidenced by loss of stem cell marker
and gain of differentiation marker expression, have enhanced migration/invasion potential.
Our findings are somewhat reminiscent to the behavior of NSCs that reside in the subventri-
cular zone of the mouse brain. These cells produce transit-amplifying progenitors, which in
turn give rise to more differentiated neuroblasts. While the NSCs remain in the subventricular
zone these neuroblasts migrate towards the olfactory bulb [31, 40–42]. Thus, it is not the stem
cells that migrate through the brain, but the more differentiated neuroblast progenitors. This is
in concurrence with a model where GSCs remain at the primary tumor site while upon differ-
entiation cells start to migrate throughout the brain forming secondary lesions (see also Fig 7).
It is possible that recurrences that are found further from the primary lesion are the result of
more differentiated cells infiltrating deeper in to the brain, and eventually under the influence
of microenvironmental cues revert back to a more undifferentiated/ SC state fueling the forma-
tion of secondary lesions with unlimited proliferative potential. An analogous de-differentia-
tion process has been detected in astrocytes that were able to revert into NSCs as a result of
Fig 6. De-differentiation of serum-differentiated GG16 cells reduces their invasive potential. a. Heatmap based on fold change of the indicated stem
cell and differentiation markers generated by qRT-PCR analyses showing partial gain of stem cell and loss of differentiation markers following
dedifferentiation of GG16 cells. b. Representative transwell membranes (magnification x5) showing reduced numbers of invading cells after dedifferentiation
of GG16 cells (secondary Nsp) that is almost equal to that of primary neurosphere cells; quantification in c. showing mean ± SEM of 3 independent
experiments (*P<0.05). d.Western blot showing the absence of MMP9 expression in primary and secondary GG16 neurosphere cells in comparison to the
differentiated GG16 cells.
doi:10.1371/journal.pone.0145393.g006
Fig 7. Model depicting the proposed effect of differentiation on GBM progression. a.Differentiation enhances the migration and invasive potential of
GBM cells. The differentiated cells can (partially) revert back to an undifferentiated/ stem cell state involving signals derived from the microenvironment. b.
During GBM progression differentiated cells emanating from the primary tumor have enhanced infiltrative capacity and penetrate deeper in to the normal
brain parenchyma. The early differentiated cells can revert back to an undifferentiated/stem cell state with unlimited proliferative potential and produce a
secondary lesion away from the primary tumor. Alternatively an additional possibility is that the more invasive differentiated GBM cells pave the way for GSCs
by generating a passage and suitable conditions for GSCs to follow their track.
doi:10.1371/journal.pone.0145393.g007
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secretory factors that were produced and released after injuring the spinal cord of adult rats
[43, 44]. Thus, similarly it is possible that GSCs after differentiation and migration to another
location are able to acquire GSC potential by de-differentiation and to regain tumor initiating
potential. This is somewhat reminiscent to an earlier proposed ‘go or grow’ model in which
GBM cells can sequentially switch from a proliferation (grow) to an invasion (go) status [45]
that is controlled by cues coming from the tumor microenvironment. An alternative or addi-
tional possibility is that migratory differentiated GBM cells first infiltrate the brain thus creat-
ing a corridor for GSCs and preparing a suitable microenvironment for GSCs to colonize the
brain. Finally, the finding that undifferentiated GBM cells/ GSCs have less migratory ability
than differentiated cells is perhaps consistent with the recurrence pattern of GBM. Around 80–
90% of GBM recurrences occur within 2cm of the primary lesion [1, 46], and may be caused by
less migratory GSCs which are known to possess high tumor forming potential [47, 48].
In conclusion, our findings support the view that not only stem-like cells are responsible for
the highly invasive phenotype of GBM, but that more differentiated GBM cells with high
migratory and invasive potential also contribute to dissemination. Thus, effective therapy
should target both GSCs and differentiated progeny in GBM and targeting of differentiation-
associated pathways may offer therapeutic opportunities to reduce invasive growth of GBM.
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